Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Watermelon Promotion Board | OTHER |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether consumption of 355 ml of watermelon juice will:
This will be determined immediately after consuming the juice (to evaluate the effects the juice has on health right away), as well as after 4 weeks of daily juice consumption (to evaluate the effects the juice has on health when consumed consistently over time).
Both hypertension and oxidative stress are among the major risk factors for cardiovascular disease (CVD). While CVD is a multifactorial disease, it has been established that diet plays an integral role in its pathogenesis. In fact, it has been previously demonstrated that almond and pomegranate consumption may be able to strengthen the body's antioxidant defense mechanisms and aid in improving several cardiometabolic health biomarkers. Watermelon, being rich in fiber, vitamins, minerals, and bioactive compounds (e.g., L-citrulline, lycopene, beta-carotene) may also have similar health effects. Notably, studies involving both mice and humans have demonstrated the potential of watermelon consumption to prevent CVD by lowering blood pressure and low-density lipoprotein cholesterol (LDL-C).
Emerging evidence suggests that postprandial biomarker levels may serve as better and earlier predictors of CVD development than their fasting levels. While watermelon is often consumed with or after a meal, no studies have evaluated the effect of watermelon on postprandial biomarker responses after a meal challenge. In addition, despite the high bioactive content of watermelon, its effects on whole-body antioxidant capacity have not been explored yet.
Therefore, in the present study it is proposed to evaluate the acute (postprandial) and chronic (4 weeks of daily consumption) effects of 355 ml of watermelon juice (WMJ) on: 1) cardiometabolic risk factors including blood pressure, heart rate, pulse wave velocity (PWV), blood glucose and lipids/lipoproteins, nitric oxide (NO), insulin/C-peptide, and GLP-1; and 2) whole-body antioxidant capacity by evaluating skin resistance to UV irritation, as well as blood and urine malondialdehyde (MDA) levels. A two-phase intervention study (2-week standardization phase and a 4-week intervention phase) involving 20 generally healthy non-vegetarian/vegan postmenopausal women with slightly elevated blood pressure, overweight/obese BMI, and Fitzpatrick's skin types II-IV will be performed. Investigating the effects of WMJ consumption on cardiometabolic risk factors and skin antioxidant defense/systemic oxidative status will uncover valuable new insights into whether bioactive compounds in watermelon can affect cardiometabolic risk and contribute to the total body antioxidant capacity.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Watermelon Juice + liquid meal test at baseline | Experimental | Acute (postprandial) as well as chronic (4 weeks) effects of WMJ consumption will be evaluated. To evaluate acute effects participants will consume a liquid meal test together with WMJ at the beginning of the intervention phase. In addition, the same liquid meal test will be consumed with only WMJ at the end of the intervention phase to assess whether drinking the juice for 4 weeks prior had any effects on postprandial responses. |
|
| Sweetened placebo beverage + liquid meal test at baseline | Placebo Comparator | Participants will consume placebo beverage + liquid meal test at baseline. They will then consume watermelon juice daily for 4 weeks. Watermelon juice + liquid meal test will be consumed at endpoint. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Watermelon Juice + liquid meal test at baseline | Other | WMJ will be purchased from a commercially available brand. The liquid meal test will be in the form of the Boost nutritional drink (8 fl.oz., vanilla flavor), which is commercially available. |
| Measure | Description | Time Frame |
|---|---|---|
| Postprandial blood pressure | To determine the acute and chronic effects of WMJ consumption on cardiometabolic health, specifically focusing on postprandial blood pressure. Previous studies showed that watermelon extract improved blood pressure management in subjects with prehypertension and hypertension and reduced arterial stiffness in postmenopausal women. Postprandial blood pressure response is recently identified to be the most sensitive postprandial clinical feature in predicting subclinical atherosclerosis. However, no study has evaluated the effect of watermelon on postprandial blood pressure. Blood pressure will be measured in mm/Hg. | Baseline and Week 4 |
| Postprandial heart rate | Will be measured in beats per minute. | Baseline and 4 weeks. |
| Postprandial pulse wave velocity | Will be measured in meters/second. | Baseline and 4 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Postprandial nitric oxide (NO) | Will be measured in µmol/L | Baseline and 4 weeks. |
| Postprandial glucose | Dysregulation of postprandial glucose and lipid responses has been implicated in the development of metabolic diseases. A previous study showed that watermelon juice consumption acutely stabilized postprandial glucose and insulin levels compared to matched sugar water in healthy subjects. Here, we will evaluate both acute and chronic effects of watermelon juice on postprandial circulating biomarker responses. |
| Measure | Description | Time Frame |
|---|---|---|
| Minimal Erythema Dose (MED) | Based on overall skin type classification, we will use the National Biological UVB mJ chart to determine the dose and sequential exposure times. Using the SPF Solar Simulator (Solar light, PA), participants' inner arm will be irradiated with a defined dose of UVB light. A total of six gradually increasing doses will be used. The subjects will return 24 hours later to determine which skin area shows minimal erythema (pink color). Photographs will be taken before irradiation and after 24 hours. The lowest dose and time of the occurrence of pink will be determined and used as MED. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tatiana Diacova, PhD, MS, RDN | Contact | 3102068292 | tdiacova@mednet.ucla.edu |
| Name | Affiliation | Role |
|---|---|---|
| Zhaoping Li, MD, PhD | University of California, Los Angeles | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCLA Center for Human Nutrition | Los Angeles | California | 90095 | United States |
Data analysis will be performed in-house.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sweetened placebo beverage +liquid meal test at baseline | Other | The placebo beverage made of water and sugar will match the sugar content provided in 355 ml of WMJ (approximately 10-20 g). The liquid meal test will be in the form of the Boost nutritional drink (8 fl.oz., vanilla flavor), which is commercially available. |
|
| Baseline and 4 weeks. |
| Postprandial blood lipids/lipoproteins (LDL cholesterol, HDL cholesterol, total cholesterol, triglycerides). | All will be measured in mg/dL. | Baseline and 4 weeks. |
| Postprandial insulin | Will be measured in international units. | Baseline and 4 weeks. |
| Postprandial C-peptide | Will be measured in nmol/L | Baseline and 4 weeks. |
| Postprandial GLP-1 | Will be measured in pmol/L | Baseline and week 4 |
| Baseline and week 4. |
| Blood and urinary malondialdehyde (MDA) concentrations | Will be measured in µM | Baseline and 4 weeks. |